Abstract LB-055: Overall survival and safety experience from an expanded access program (EAP) of nivolumab (NIVO) for patients with advanced melanoma (MEL) who progressed after prior ipilimumab (IPI) treatment

Authors

Suresh G. Nair MD, Lehigh Valley Health NetworkFollow

Publication/Presentation Date

7-2017

Volume

77

Issue

13

Published In/Presented At

https://aacrjournals.org/cancerres/article/77/13_Supplement/LB-055/622239/Abstract-LB-055-Overall-survival-and-safety?searchresult=1

Disciplines

Medicine and Health Sciences

Department(s)

Department of Medicine

Document Type

Article